Literature DB >> 22981431

Protective role of clusterin in preserving endothelial function in AL amyloidosis.

Daniel A Franco1, Seth Truran, Camelia Burciu, David D Gutterman, Anthony Maltagliati, Volkmar Weissig, Parameswaran Hari, Raymond Q Migrino.   

Abstract

UNLABELLED: Misfolded immunoglobulin light chain proteins (LC) in light chain amyloidosis (AL) are toxic to vascular tissues. We tested the hypothesis that chaperone protein clusterin preserves endothelial function and cell survival during LC exposure.
METHODS: LC (20 μg/mL) were given to human aortic endothelial cells (EC) for 24-h and clusterin protein/gene expression and secretion were measured. DNA fragmentation was measured with/without recombinant clusterin (Clu, 300 ng/mL). Adipose arterioles (non-AL subjects) were tested for dilator responses to acetylcholine/papaverine at baseline and after 1-h of LC ± Clu.
RESULTS: LC reduced EC clusterin secretion, protein and gene expression while increasing DNA fragmentation. Clu attenuated LC-induced DNA fragmentation and restored dilator response to acetylcholine (logEC50: control -7.05 ± 0.2, LC + Clu -6.53 ± 0.4, LC -4.28 ± 0.7, p < 0.05 versus control, LC + Clu).
CONCLUSIONS: LC induced endothelial cell death and dysfunction while reducing clusterin protein/gene expression and secretion. Exogenous clusterin attenuated LC toxicity. This represents a new pathobiologic mechanism and therapeutic target for AL amyloidosis. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22981431      PMCID: PMC3478430          DOI: 10.1016/j.atherosclerosis.2012.08.028

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  14 in total

1.  Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

Authors:  Giovanni Palladini; Francesca Lavatelli; Paola Russo; Stefano Perlini; Vittorio Perfetti; Tiziana Bosoni; Laura Obici; Arthur R Bradwell; GianVico Melzi D'Eril; Roberto Fogari; Remigio Moratti; Giampaolo Merlini
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

2.  Amyloidosis of epicardial and intramural coronary arteries as an unusual cause of myocardial infarction and refractory angina pectoris.

Authors:  Daniela Miani; Maurizio Rocco; Ezio Alberti; Leonardo Spedicato; Paolo Maria Fioretti
Journal:  Ital Heart J       Date:  2002-08

3.  Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins.

Authors:  Raymond Q Migrino; Seth Truran; David D Gutterman; Daniel A Franco; Megan Bright; Brittany Schlundt; Mitchell Timmons; Angelica Motta; Shane A Phillips; Parameswaran Hari
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-30       Impact factor: 4.733

4.  Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis.

Authors:  P S Mueller; W D Edwards; M A Gertz
Journal:  Am J Med       Date:  2000-08-15       Impact factor: 4.965

5.  Vascular abnormalities in primary amyloidosis.

Authors:  Karen M Modesto; Angela Dispenzieri; Morie Gertz; Sanderson A Cauduro; Bijoy K Khandheria; James B Seward; Robert Kyle; Christina M Wood; Kent R Bailey; Abdel Jamil Tajik; Fletcher A Miller; Patricia A Pellikka; Theodore P Abraham
Journal:  Eur Heart J       Date:  2007-04-12       Impact factor: 29.983

6.  Oxidative stress is found in amyloid deposits in systemic amyloidosis.

Authors:  Y Ando; N Nyhlin; O Suhr; G Holmgren; K Uchida; M el Sahly; T Yamashita; H Terasaki; M Nakamura; M Uchino; M Ando
Journal:  Biochem Biophys Res Commun       Date:  1997-03-17       Impact factor: 3.575

7.  Left ventricular ejection time on echocardiography predicts long-term mortality in light chain amyloidosis.

Authors:  Raymond Q Migrino; Ravi K Mareedu; Daniel Eastwood; Mark Bowers; Leanne Harmann; Parameswaran Hari
Journal:  J Am Soc Echocardiogr       Date:  2009-10-31       Impact factor: 5.251

8.  Endothelial dysfunction precedes C-fiber abnormalities in primary (AL) amyloidosis.

Authors:  Martin Berghoff; Madeera Kathpal; Faisal Khan; Martha Skinner; Rodney Falk; Roy Freeman
Journal:  Ann Neurol       Date:  2003-06       Impact factor: 10.422

Review 9.  Clusterin: a forgotten player in Alzheimer's disease.

Authors:  Tapio Nuutinen; Tiina Suuronen; Anu Kauppinen; Antero Salminen
Journal:  Brain Res Rev       Date:  2009-08-03

10.  Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.

Authors:  Madhav Thambisetty; Andrew Simmons; Latha Velayudhan; Abdul Hye; James Campbell; Yi Zhang; Lars-Olof Wahlund; Eric Westman; Anna Kinsey; Andreas Güntert; Petroula Proitsi; John Powell; Mirsada Causevic; Richard Killick; Katie Lunnon; Steven Lynham; Martin Broadstock; Fahd Choudhry; David R Howlett; Robert J Williams; Sally I Sharp; Cathy Mitchelmore; Catherine Tunnard; Rufina Leung; Catherine Foy; Darragh O'Brien; Gerome Breen; Simon J Furney; Malcolm Ward; Iwona Kloszewska; Patrizia Mecocci; Hilkka Soininen; Magda Tsolaki; Bruno Vellas; Angela Hodges; Declan G M Murphy; Sue Parkins; Jill C Richardson; Susan M Resnick; Luigi Ferrucci; Dean F Wong; Yun Zhou; Sebastian Muehlboeck; Alan Evans; Paul T Francis; Christian Spenger; Simon Lovestone
Journal:  Arch Gen Psychiatry       Date:  2010-07
View more
  9 in total

Review 1.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

Review 2.  The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases.

Authors:  S Park; K W Mathis; I K Lee
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

3.  Nanoliposomes protect against AL amyloid light chain protein-induced endothelial injury.

Authors:  Seth Truran; Volkmar Weissig; Marina Ramirez-Alvarado; Daniel A Franco; Camelia Burciu; Joseph Georges; Shishir Murarka; Winter A Okoth; Sara Schwab; Parameswaran Hari; Raymond Q Migrino
Journal:  J Liposome Res       Date:  2013-11-15       Impact factor: 3.648

4.  Adipose and leptomeningeal arteriole endothelial dysfunction induced by β-amyloid peptide: a practical human model to study Alzheimer's disease vasculopathy.

Authors:  Seth Truran; Daniel A Franco; Alex E Roher; Thomas G Beach; Camelia Burciu; Geidy Serrano; Chera L Maarouf; Sara Schwab; Jenna Anderson; Joseph Georges; Peter Reaven; Raymond Q Migrino
Journal:  J Neurosci Methods       Date:  2014-07-05       Impact factor: 2.390

5.  Clinical and imaging predictors of 1-year and long-term mortality in light chain (AL) amyloidosis: a 5-year follow-up study.

Authors:  Raymond Q Migrino; Leanne Harmann; Richard Christenson; Parameswaran Hari
Journal:  Heart Vessels       Date:  2013-10-19       Impact factor: 2.037

6.  Nanoliposomes protect against human arteriole endothelial dysfunction induced by β-amyloid peptide.

Authors:  Seth Truran; Volkmar Weissig; Jillian Madine; Hannah A Davies; Diana Guzman-Villanueva; Daniel A Franco; Nina Karamanova; Camelia Burciu; Geidy Serrano; Thomas G Beach; Raymond Q Migrino
Journal:  J Cereb Blood Flow Metab       Date:  2015-10-08       Impact factor: 6.200

7.  Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins.

Authors:  Daniel A Franco; Seth Truran; Volkmar Weissig; Diana Guzman-Villanueva; Nina Karamanova; Subhadip Senapati; Camelia Burciu; Marina Ramirez-Alvarado; Luis M Blancas-Mejia; Stuart Lindsay; Parameswaran Hari; Raymond Q Migrino
Journal:  J Am Heart Assoc       Date:  2016-06-13       Impact factor: 5.501

8.  PEGylated-nanoliposomal clusterin for amyloidogenic light chain-induced endothelial dysfunction.

Authors:  Diana Guzman-Villanueva; Raymond Q Migrino; Seth Truran; Nina Karamanova; Daniel A Franco; Camelia Burciu; Subhadip Senapati; Dobrin Nedelkov; Parameswaran Hari; Volkmar Weissig
Journal:  J Liposome Res       Date:  2017-02-10       Impact factor: 3.648

Review 9.  Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood.

Authors:  Antonio Mastrangelo; Jessica Serafinelli; Marisa Giani; Giovanni Montini
Journal:  Front Pediatr       Date:  2020-05-12       Impact factor: 3.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.